Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Fig. 2

The Forrest plot of PFS for patients with HR+/HER2- advanced breast cancer after progression on ≥ 1 line of endocrine treatment. A PFS pooled result for overall patients; B PFS pooled result for patients with previous use of CDK4/6 inhibitors; C PFS pooled result for patients with ESR1m; D PFS pooled result for comparing oral SERDS with fulvestrant in patients with ESR1m subgroup. Note: PFS, progression-free survival; CI, confidence interval; HR, hazard ratio; HR+/HER2-, hormone receptor-positive and human epidermal growth factor receptor 2-negative; SERDs, selective estrogen receptor degraders; ESR1m, estrogen receptor 1 mutations

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us